Deepcell Secures $73 Million in Series B  

by Kay Aloha Villamor in March 18th, 2022

Deepcell, a Menlo Park, CA-based life science company pioneering AI-powered single-cell classification and isolation for basic and translational research, announced that it closed its $73 million Series B round of financing. This Series B financing brings Deepcell’s overall funding to nearly $100 million since the company was founded in 2017.

This round of funding was led by Koch Disruptive Technologies and joined by new investors including Bridger Healthcare, Horizons Ventures, Casdin Capital and lead investors from previous rounds, Andreessen Horowitz and Bow Capital as well as Jeff Dean, Head of Google Brain, and Matt Mcllwain, Managing Director at Madrona Venture Group. 

The new funding will allow Deepcell to continue product development and enable the early commercial introduction of a new standard for obtaining biological insights from single-cell analysis. 

Company: Deepcell, Inc.

Raised: $73.0M

Round: Series B

Funding Month: March 2022

Lead Investors: Koch Disruptive Technologies

Additional Investors: Bridger Healthcare, Horizons Ventures, Casdin Capital, Andreessen Horowitz, Bow Capital, Jeff Dean, and Matt Mcllwain

Company Website:

Software Category: AI-Powered Single Cell Analysis Platform

About the Company: Deepcell is helping to advance precision medicine by combining advances in AI, cell classification and capture, and single-cell analysis to deliver novel insights through an unprecedented view of cell biology. Spun out of Stanford University in 2017, the company has created unique, microfluidics-based technology that uses continuously learning AI to classify cells based on detailed visual features and sort them without inherent bias. The Deepcell platform maintains cell viability for downstream single-cell analysis and can be used to isolate virtually any type of cell, even those occurring at frequencies as low as one in a billion. The technology will initially be available as a service for use in translational research as well as diagnostics and therapeutic development. Deepcell is privately held and based in Menlo Park, CA. 



Your cart